FluoretiQ Limited (FQ)

FluoretiQ Limited (FQ) was founded to solve the £1.1 Bn problem of using broad spectrum antibiotics as an alternative for accurate diagnosis of infection. As a result, 70% of AMR deaths across the world are caused by resistance to first-line antibiotics. Rapid diagnostics are a readily accessible and effective tool to support critical antibiotic stewardship decisions. We are building a family of complimentary diagnostic tools to critically improve the speed and quality of information available to every clinician. Our mission is to champion Antibiotic Stewardship resulting in superior patient outcomes whilst cutting the time and cost of quality healthcare.